Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sierra Oncology, Inc. - Common Stock (NQ: SRRA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sierra Oncology, Inc. - Common Stock

< Previous 1 2 3 Next >
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sierra Oncology
Via Business Wire
Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development
Sierra Oncology Inc (NASDAQ: SRRA) has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant. 
Via Benzinga
Sierra Oncology to Participate in Guggenheim Oncology Conference
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
From Sierra Oncology
Via Business Wire
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
From Sierra Oncology
Via Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,... 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
41 Biggest Movers From Yesterday
Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave... 
Via Benzinga
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
From Sierra Oncology
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Rani Therapeutics Hldgs (NASDAQ:RANI 
Via Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 32% to $0.7262 after the company announced a share buyback of up to 100 million shares of common stock at $1 per share... 
Via Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
18 Stocks Moving in Wednesday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food Group, Inc. (NASDAQ: BRFH) shares rose 31.7% to $... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients... 
Via Benzinga
Sierra Oncology Announces Proposed Public Offering of Common Stock
From Sierra Oncology
Via Business Wire
Mid-Afternoon Market Update: Dow Turns Higher; General Electric Shares Slide
Toward the end of trading Tuesday, the Dow traded up 0.12% to 34,405.65 while the NASDAQ fell 1.19% to 13,690.05. The S&P also fell, dropping, 0.57% to 4,384.81. The U.S... 
Via Benzinga
Mid-Day Market Update: Nasdaq Tumbles 300 Points; Sierra Oncology Shares Jump
Midway through trading Tuesday, the Dow traded down 1.15% to 33,968.17 while the NASDAQ fell 2.20% to 13,549.98. The S&P also fell, dropping, 1.68% to 4,336.24. The U.S. has... 
Via Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,... 
Via Benzinga
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
Sierra Oncology spent just $3 million up front to acquire momelotinib. 
Via Investor's Business Daily
Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development
Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential... 
Via Benzinga
Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal
Sierra Oncology Inc (NASDAQ: SRRA) unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sierra Oncology (NASDAQ:SRRA) stock rose 45.6% to $22.58 during Tuesday's pre-market session. The market value of their outstanding shares is at $339.9 million... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
Via Benzinga
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
From Sierra Oncology
Via Business Wire
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
From Sierra Oncology
Via Business Wire
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.